Advertisement

Index by author

February 01, 1996; Volume 276,Issue 2

  1. Eddy, E P

    1. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
      E H Ohlstein, P Nambi, A Lago, D W Hay, G Beck, K L Fong, E P Eddy, P Smith, H Ellens and J D Elliott
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 609-615;

  2. Ehlert, F J

    1. The quaternary transformation products of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) have differential affinity for subtypes of the muscarinic receptor.
      F J Ehlert, H S Oliff and M T Griffin
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 405-410;

  3. Eissenberg, T

    1. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
      T Eissenberg, M K Greenwald, R E Johnson, I A Liebson, G E Bigelow and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 449-459;

  4. Ellens, H

    1. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
      E H Ohlstein, P Nambi, A Lago, D W Hay, G Beck, K L Fong, E P Eddy, P Smith, H Ellens and J D Elliott
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 609-615;

  5. Elliott, J D

    1. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
      E H Ohlstein, P Nambi, A Lago, D W Hay, G Beck, K L Fong, E P Eddy, P Smith, H Ellens and J D Elliott
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 609-615;
Back to top

In this issue

Advertisement